Sr. Director, Biology at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

BSc in biology, biochemistry or pharmacology
PhD in biology, pharmacology or similar
15+ years of relevant industrial experience
Experience in multiple therapeutic areas, ideally including oncology
People management experience
Strong communication skills and ability to work well in a matrixed environment
Currently authorized to work in the United States on a full-time basis

Responsibilities

Provide expert strategic guidance on all aspects of non-clinical biology
Partner with Director of Medicinal Chemistry and CSO to design and implement screening cascade for testing new compounds
Plan and execute all non-clinical experiments
Collaborate with clinical development group; lead development of non-clinical strategies for current and future development programs
Develop strong working relationships with translational scientists
Serve as expert point of contact and resource for ongoing scientific experiments
Source, select and manage appropriate contract research vendors, including third-party staff and budget oversight
Support existing academic collaborations and identify potential new partnerships, as appropriate
Contribute to scientific publications and patents
Manage an Associate Director of Biology

Skills

Non-Clinical Biology

Medicinal Chemistry

Screening Cascade

Experiment Design

Clinical Development

Translational Science

Vendor Management

Budget Oversight

Academic Collaborations

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free